Статины при остром коронарном синдроме
Автор: Аляви Анис Лютфуллаевич, Кенжаев Сирожиддин Рашидович, Алимов Данияр Анварович, Кенжаев Мажид Латипович, Рахимова Рано Абдухакимовна, Койиров Акмал Камбарович, Мирмаксудов Мирахмад
Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal
Рубрика: Обзор
Статья в выпуске: 1, 2019 года.
Бесплатный доступ
В статье обобщены результаты последних исследований (ARMYDA, NAPLES II, MIRACL, ARMYDA-ACS, JUPITER, LUNAR) с использованием в клинической практике ингибиторов гидрок-симетилглутарил-КоА-редуктазы (статинов) у больных с острым коронарным синдромом, в том числе у лиц, подвергшихся чрескожному коронарному вмешательству. Клиническими и экспериментальными исследованиями доказаны липидоснижающие, про тивовоспалительные и другие плейотропные эффекты статинов при острых формах ишемической болезни сердца. Авторами изучено также влияние статинов на оглушенный миокард, реперфузионное повреждение миокарда при остром инфаркте миокарда.
Статин, плейотропный эффект, острый коронарный синдром, чрескожные коронарные вмешательства
Короткий адрес: https://sciup.org/143170027
IDR: 143170027
Список литературы Статины при остром коронарном синдроме
- Курбанов Р.Д. Клинические протоколы диагностики и лечения сердечно-сосудистых заболеваний. Ташкент 2014.
- Alyavi A.L., Kenjaev S. et al. Influence of high dose atorvastatin on myocardial stunning in acute myocardial infarction. Atherosclerosis 2017; 263: e245.
- Atalar E., Coskun S., Haznedaroglu I.C. et al. Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes. Cardiovasc Drugs Ther 2005; 19 (3): 177-81.
- Baigent C., Keech A, Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267-78.
- Briguori C., Visconti G., Focaccio A. et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Amer Coll Cardiol 2009; 54 (23): 2157-63.
- Cannon C.P., Braunwald E, McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004; 350 (15): 1495-504.
- Cardiovascular diseases. WHO Fact sheet №317. Updated 2017 May.
- de Lemos J.A., Blazing M.A., Wiviott S.D. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292 (11): 1307-16.
- Pasceri V., Patti G., Nusca A. et al. ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.. Circulation 2004; 110 (6): 674-8.
- Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Amer Coll Cardiol 2009; 54 (6): 558-65.
- Glynn R.J., Danielson E., Fonseca F.A. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New Engl J Med 2009; 360 (18): 1851-61.
- Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Europ Heart J 2018; 39 (2): 119-77.
- Luzak B., Rywaniak J., Stanczyk L., Watala C. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. Europ J Clin Invest 2012; 42 (8): 86472.
- Moscardo A, Valles J., Latorre A. et al. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thromb Res 2013; 131 (4): e154-9.
- Mozaffarian D., Benjamin E.J., Go A.S. et al. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation 2016; 133: e38-e60.
- O'Gara P.T., Kushner F.G,. Ascheim D.D. et al. 2013 ACCF/ AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127 (4): e362-425.
- Pasceri V, Patti G., Nusca A. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004; 110 (6): 674-8.
- Patti G., Cannon C.P., Murphy S.A. et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123 (15): 1622-32.
- Patti G., Pasceri V, Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes un dergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Amer Coll Cardiol 2007; 49 (12): 1272-8.
- Pitt B., Loscalzo J., Monyak J. et al. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Amer J Cardiol 2012; 109 (9): 1239-46.
- Ray K.K., Cannon C.P. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management ofacute coronary syndromes. J Amer Coll Cardiol 2005; 46 (8): 1425-33.
- Rezaie-Majd A, Prager G.W., Bucek R.A. et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003; 23 (3): 397-403.
- Ridker P.M., Danielson E., Fonseca F.A. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373 (9670): 1175-82.
- Rodriguez A.L., Wojcik B.M., Wrobleski S.K. et al. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 2012; 33 (4): 371-82.
- Sanguigni V, Pignatelli P., Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111 (4): 412-9.
- Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (13): 1711-8.
- Sposito A.C., Santos S.N., de Faria E.C. et al. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol 2011; 31 (5): 1240-6.
- Stefanadi E., Tousoulis D., Antoniades C. et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. Int J Cardiol 2009; 133 (2): 266-8.
- Theroux P., Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97 (12): 1195-206.
- Tousoulis D., Bosinakou E., Kotsopoulou M. et al. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol 2006; 106 (3): 333-7.
- Undas A, Celinska-Lowenhoff M., Brummel-Ziedins K.E. et al. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2005; 25 (7): 1524-5.
- Pignatelli P, Sanguigni Vat al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Journal of thrombosis and hemostasis. Vol. 5, Iss 6. 2007 P.1170-1178
Статья обзорная
